Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1. Introduction High-risk neuroblastoma (HR-NB) represents approximately half of all NB patients. Even with the current standard of care for HR-NB, including high-dose chemotherapy (HDC) and surgery (induction phase), followed by hematopoietic autologous stem cell transplantation (ASCT) and radiation (consolidation phase), and anti-GD2 immunotherapy and retinoic acid (maintenance phase), the five-year event-free survival (EFS) remains below 60% [1].
Abstract : Simple Summary Despite being in use for almost 50 years, monoclonal antibodies face limitations in their implementation in clinical practice, particularly in pediatrics and pediatric cancer. Although technological advancements and research into new therapeutic targets have led to the development of sophisticated and effective molecules, translational barriers still exist.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
